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Abstract  The  term  ‘‘second  look’’  lesions  in  MRI  refers  to  lesions  detected  by  MRI  that
were not  initially  seen  on  mammography  or  ultrasound.  The  objectives  of  our  study  were  to
analyse the  displacement  of  targets  between  MRI  and  ultrasound;  to  deﬁne  discriminating
BIRADS morphological  criteria  to  predict  benign  or  malignant  character  and  better  estab-
lish the  indications  of  second  look  ultrasound  and  biopsy;  and  to  analyse  the  agreement
between  ultrasound  and  MRI  in  terms  of  morphological  criteria.  A  retrospective  and  mono-
centric review  was  performed  of  the  records  of  consecutive  patients  with  breast  abnormalities
(mass or  non-mass)  initially  detected  by  MRI  that  were  not  initially  seen  on  mammography
or ultrasound.  All  patients  with  abnormalities  found  during  the  performance  of  second  look
ultrasound and  biopsied  were  included  in  the  study.  All  lesions  were  documented  using  the
BIRADS lexicon  for  MRI  and  ultrasound.  Of  100  included  patients,  108  lesions  were  detected
by MRI,  found  via  second  look  ultrasound  and  biopsied  between  January  2008  and  2010.
All of  the  included  patients  were  followed-up  for  a  variable  period,  from  2  to  5  years.
Eighty-two  upon  108  biopsied  lesions  (76%)  were  benign  and  26/108  lesions  (24%)  were  malig-
nant. This  study  conﬁrmed  the  switch  from  procubitus  to  decubitus  essentially  displaces
the tumour  in  the  antero-posterior  direction.  It  showed  that  the  risk  factors  were  not
reliable criteria  for  establishing  an  indication  for  second  look  ultrasound.  This  study  also
showed that  circumscribed  contours  and  a  progressive  enhancement  curve  (type  I)  for  masses
on MRI  had  the  strongest  negative  predictive  value  of  greater  than  0.85.  In  ultrasound,
Abbreviations: IDC, Invasive ductal carcinoma; ILC, Invasive lobular carcinoma; DCIS, Ductal carcinoma in situ; MRI, Magnetic resonance
imaging; MPR, Multi planar reconstruction; LEQ, Lower external quadrant; LIQ, Lower internal quadrant; UEQ, Upper external quadrant; UIQ,
Upper internal quadrant; NME, Non-masslike enhancement; JEQ, Junction of the external quadrants; JLQ, Junction of the lower quadrants;
JIQ, Junction of the internal quadrants; UQS, Junction of the upper quadrants.
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the  round  or  oval  shape,  circumscribed  contours  and  the  parallel  orientation  to  the  skin  favoured
benignity with  a  NPV  of  greater  than  0.85.  For  masses,  the  study  showed  that  the  agreement  in
interpretation  of  the  benign  versus  suspicious  morphological  criteria  between  the  MRI  and  the
ultrasound  was  very  weak  for  the  shape  (Kappa  =  0.09)  and  weak  for  the  contours  (Kappa  =  0.23).
Finally, the  MRI  overestimated  the  size  of  the  targets  compared  to  ultrasound  (Student  t-test,
p =  0.0001).  The  performance  of  second  look  ultrasound  has  to  be  performed  after  the  detection
of an  abdnormality  on  MRI  even  for  lesion  classiﬁed  BIRADS  3.  The  biopsy  indications  must  be
wide with  insertion  of  a  clip  and  a  control  MRI.  Only  this  control  allows  to  stop  the  investigation
if the  biopsied  lesion  is  benign.
© 2014  Published  by  Elsevier  Masson  SAS  on  behalf  of  the  Éditions  françaises  de  radiologie.
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he  term  ‘‘second  look’’  lesions  in  MRI  refers  to  lesions
etected  by  MRI  that  were  not  initially  seen  on  mammog-
aphy  or  ultrasound.  In  a  recent  meta-analysis  evaluating
he  role  of  MRI  in  the  detection  of  these  additional  tumours
n  the  homolateral  breast,  the  prevalence  of  detection  was
pproximately  16%  (between  6  and  34%)  with  a  positive  pre-
ictive  value  of  66%  [1].  A  histological  control  is  therefore
ften  useful  when  faced  with  the  discovery  of  additional
ew  lesions  by  MRI  before  choosing  a  treatment  in  order  to
educe  false  positives  and  to  avoid  useless  mastectomies  in
ase  of  falsely  malignant  additional  lesions.
Compared  to  MR-guided  biopsies,  ultrasound-guided
iopsies  are  easier,  faster,  less  expensive,  more  accessi-
le  (fewer  MRI  machines),  less  anatomically  limited  (deep
nd  axillary  internal  lesions)  and  more  comfortable  for  the
atients.  In  addition,  biopsies  performed  under  MRI  do  not
llow  for  real  time  control  during  biopsy.  The  underesti-
ation  rate  of  MR-guided  biopsies  of  risky  lesions  such  as
typical  ductal  hyperplasia  could  be  38%,  i.e.  18%  higher
han  under  stereotaxis  [2].
We  therefore  looked  at  the  performance  of  second  look
ltrasound  based  ﬁrst  on  the  review  of  the  literature  and
econd  on  the  data  from  a  retrospective  study  concerning:
the  analysis  of  the  displacement  of  targets  between  MRI
and  ultrasound;
screening  for  discriminating  BIRADS  morphological  crite-
ria  to  predict  benign  or  malignant  character  and  better
establish  the  indications  of  second  look  ultrasound  and
biopsy;
the  analysis  of  the  agreement  between  ultrasound  and  MRI
in  terms  of  morphological  criteria.
atients and methods
atients
 retrospective  study  was  conducted  at  the  Saint  Louis  Uni-
ersity  Hospital  Centre.  Between  January  2008  and  2010,
ll  patients  who  had  a  breast  MRI  detecting  an  abnormal-
ty  that  was  not  seen  during  a  prior  evaluation  including
ammography  and/or  ultrasound  found  during  the  perfor-
ance  of  second  look  ultrasound  and  biopsy  were  included  in
he  study.  No  calciﬁcation  or  mass-type  abnormalities  were
ound  on  the  mammography  in  the  corresponding  region
(
a
g
and  there  was  no  obvious  palpable  lesion.  Hundred  consec-
tive  patients  were  included  according  to  these  inclusion
riteria.  The  indications  for  breast  MRI  were  as  follows:
re-treatment  evaluation  of  breast  cancer  (invasive  lobular
arcinoma  or  locally  advanced  invasive  ductal  carcinoma)
onﬁrmed  by  histology  (n  =  41/100),  screening  of  patients
ith  a family  history  with  more  than  three  affected  family
embers  (n  =  19/100,  including  5  BRCA1/2  patients),  moni-
oring  of  patients  with  a  personal  history  of  breast  cancer
n  = 15/100),  exploration  of  an  abnormality  detected  by
ammography  or  ultrasound  (n  =  15/100),  exploration  of  a
linical  abnormality  such  as  axillary  adenopathy  (n  =  3/100),
ipple  retraction  (n  =  5/100)  or  breast  discharge  (n  =  2/100)
ithout  an  abnormality  found  by  initial  ultrasound  or  mam-
ography.  All  of  the  patients  included  in  the  study  had  a
linical  examination,  mammography  and  ultrasound  before
he  MRI.  Lesions  that  were  already  known  before  the  MRI
ere  excluded  from  the  study.  Only  the  lesions  that  had  not
een  detected  by  the  clinical  examination,  mammography
nd  ultrasound  were  included  in  the  study.  The  age  of  the
ncluded  patients  was  between  29  and  79  years,  with  a  mean
ge  of  48.9  years.
RI
ll  the  patients  had  a  bilateral  breast  MRI  on  the  same
RI  machine  (MRI  1.5  Tesla,  Siemens  Symphony  TIM,  Erlan-
en,  Germany),  but  the  protocol  followed  was  not  always
xactly  the  same.  However  all  of  the  protocols  included
n  axial  T2  sequence  with  or  without  saturation  of  the
at  signal  (TR  msec/TE  msec,  1300/242;  ETL  189,  matrix,
84  ×  384;  FOV,  320  ×  320  mm;  jointed  cuts,  1.2  mm),  and
ynamic  axial  T1  sequences  without  and  then  with  injec-
ion  of  contrast  material  (Dotarem®,  Guerbet,  France)  with
PR  and  MIP  reconstruction  and  subtraction  (TR  msec/TE
sec,  4.67/1.65;  ﬂip  angle,  12◦;  matrix,  320  ×  320;  FOV,
80  ×  320  mm;  jointed  cuts,  1.2  mm).
All  of  the  MRIs  were  reread  by  two  radiologists  (1  and
0  years  of  experience  in  breast  MRI)  for  inclusion  in  the
tudy  and  based  on  the  BIRADS  lexicon.  The  detected  lesions
ll  had  enhancement  abnormalities:  focal  lesion,  mass  and
on-mass.  For  the  masses,  the  size,  exact  location  (quad-
ants,  hour,  depth,  distance  with  regard  to  the  nipple),  form
round,  oval  or  irregular),  contours  (circumscribed,  irregular
nd  spiculated),  the  kind  of  internal  enhancement  (homo-
eneous,  heterogeneous,  existence  of  non-enhanced  septa
nd  annular  enhancement,  as  well  as  the  curve  type)  and  the
rasou
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BIRADS  were  described.  For  non-masses,  their  distribution
(focus,  focal  area,  linear-type  non-masslike  enhancement,
segmentary,  regional,  diffuse)  as  well  as  their  internal
enhancement  (homogeneous,  heterogeneous,  homogeneous
or  annular  micronodular  character)  and  the  BIRADS  classiﬁ-
cation  were  described.
Of  these  100  patients,  108  lesions  were  detected  by  MRI
and  found  on  the  second  look  ultrasound.
Second look ultrasound
All  of  the  patients  had  a  targeted  second  look  ultra-
sound  (Aixplorer®,  Supersonic  Imaging,  France)  within  a
mean  of  4  days.  It  should  be  noted  that  42  of  100  patients
had  second  look  ultrasound  immediately  after  the  per-
formance  of  the  MRI.  The  lesion(s)  detected  by  MRI
and  found  on  the  ultrasound  were  described  by  the
operator  at  the  time  of  the  performance  of  the  ultra-
sound  as  per  the  BIRADS  terminology.  The  location  of
the  mass  (quadrant,  depth,  hour),  its  size,  shape  (round,
oval,  irregular),  contours  (circumscribed,  irregular,  spic-
ulated),  orientation  (vertical,  horizontal),  echogenicity
(hypo/iso/hyperechogenic,  heterogenic),  the  existence  of
acoustic  particularities  (attenuation,  reinforcement)  as  well
as  the  BIRADS  classiﬁcation  were  described.  Following  the
second  look  ultrasound,  the  detected  lesion(s)  were  all  biop-
sied.  The  mean  time  between  the  performance  of  the  MRI
and  the  biopsy  was  10.1  days.
For  each  biopsied  lesion,  two  to  four  samples  were  taken
using  a  16  to  14  G  coaxial  system.  One  in  two  samples  was
ﬁxed  in  alcohol  formalin  acetic  acid  (AFA),  and  the  other
half  of  the  samples  was  frozen  in  liquid  hydrogen.  The  sam-
ples  were  all  analysed  at  the  Saint  Louis  hospital  by  the  same
pathologist  (20  years  of  experience  in  breast  pathology).  The
histological  and  anatomical  pathology  information  was  col-
lected  from  reports  primarily  with  the  malignant  or  benign
nature  of  the  biopsied  abnormality.  For  the  benign  lesions,
we  distinguished  between  the  following  diagnoses:  healthy
breast  tissue,  adenoﬁbroma,  ﬁbrocystic  dystrophy,  ﬁbrous
restructuring,  papilloma/papillary  cystadenoma  without
atypia,  other  benign  pathologies  (adenosis,  cylindrical
metaplasia,  intra-epithelial/intra-ductal/lobular  hyperpla-
sia  without  atypia,  desmoid  ﬁbroma)  and  hyperplasia  with
atypia.  For  malignant  lesions,  we  distinguished  between
the  type  of  carcinoma  (invasive  or  in  situ  lobular/ductal),
the  grade  and  the  existence  of  hormone  receptors  (oestro-
gen  and  progesterone)  as  well  as  the  overexpression  or
non-overexpression  of  CerB2.  For  operated  lesions,  the
concordance  between  the  histological  examination  of  the
biopsy  samples  and  that  of  the  removed  piece  was  checked.
Follow-up
All  of  the  included  patients  had  biopsies  and  were  then
followed-up  for  a  variable  period  after  their  biopsy  (from
2  to  5  years)  with  different  imaging  modalities  (mammog-
raphy,  ultrasound  or  MRI)  according  to  their  personal  and
family  medical  histories  and  the  nature  of  the  lesions  identi-
ﬁed  on  the  MRI  that  were  biopsied.  In  all  cases,  the  follow-up
modalities  included  at  least  one  clinical  examination,  and
most  often  a  control  mammography  or  ultrasound  in  combi-
nation  or  not  in  combination  with  MRI.
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tatistics
he  statistics  were  performed  using  the  Analyse-It  software
rogramme  (United  Kingdom).  The  comparisons  of  the  rates
f  cancer  compared  to  the  rates  of  benign  lesions  found
ia  the  second  look  biopsy  based  on  risk  factors  and  depth
r  based  on  the  MRI  and  ultrasound  appearance  as  per  the
IRADS  classiﬁcation  were  made  using  the  Fisher  test.  The
ifferences  in  size  on  MRI  between  the  benign  and  malignant
ature  determined  by  the  second  look  ultrasound  biopsy
ere  measured  using  the  Student’s  t-test.
The  comparison  of  the  topography  of  the  lesions  between
he  MRI  and  the  ultrasound  was  carried  out  using  the  Kappa
est.
The  differences  in  the  measurement  of  the  distance
etween  the  lesion  and  the  nipple  between  the  MRI  and
econd  look  ultrasound  and  the  differences  in  the  measure-
ent  of  lesion  size  between  the  MRI  and  the  second  look
ltrasound  were  evaluated  using  Student’s  t-test.
esults
f  100  included  patients,  108  lesions  were  detected
y  MRI,  found  via  second  look  ultrasound  and  biop-
ied.  82/108  biopsied  lesions  (76%)  were  benign  and
6/108  lesions  (24%)  were  malignant.  (Fig.  1).  Of  the  benign
esions,  40%  (43/108)  were  ﬁbrous  lesions.  This  high  rate
ould  be  partially  explained  by  the  medical  history  of  the
atients  (surgery  and  radiotherapy)  (Fig.  2).  The  propor-
ions  of  malignant  lesions  increased  with  the  depth  (Fig.  3)
ithout  a  signiﬁcant  different  (Fisher  test,  P  >  0.78).
ancer rates according to the indications
here  was  not  more  cancer  in  the  population  at  risk  (patient
ith  a mutation,  history  of  breast  cancer  at  a  young  age,
amily  history,  pre-surgical  evaluation),  (n  =  20/86,  23%)
han  in  the  population  that  was  not  at  risk  (n  =  7/26,  27%,
isher  test,  P =  0.7944).  In  particular,  in  patients  with  a
utation  (n  =  5)  or  with  a family  history  of  breast  cancer
n  =  22),  no  lesions  biopsied  on  a  second  look-basis  were
ancerous.  The  breast  cancer  rate  was  not  statistically  dif-
erent  in  patients  with  a  history  of  breast  cancer  at  a  young
ge  (n  =  7/19,  37%)  compared  to  the  population  that  was
ot  at  risk  (n  =  7/31,  23%,  Fisher  test,  P  =  0.3385).  In  case
f  a  local  extent  evaluation,  the  rate  of  additional  lesions
ound  on  a  second  look-basis  was  not  statistically  higher
n  =  13/41,  32%)  compared  to  the  population  that  was  not  at
isk  (n  =  10/37,  27%,  Fisher  test,  P  =  0.8043).  Of  the  clinical
ndications,  two  cases  of  cancer  were  found  in  patient  for
creening  for  the  primary  metastatic  axillary  adenopathy,
ne  case  of  cancer  was  found  in  two  patients  with  discharge
rom  the  breast  and  one  case  of  cancer  was  found  out  of  ﬁve
atients  with  nipple  retraction.
isplacementhe  study  showed  that  the  antero-posterior  displacement
f  lesions  is  high  between  the  MRI  and  the  ultrasound  with
oderate  agreement  between  the  two  methods  in  terms
f  the  position  of  lesions  in  anterior,  middle  or  posterior
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Figure 1. Histogram showing the histological results of the 108 lesions detected on the MRI, found on the second look ultrasound and biop-
sied. The ‘‘other benign’’ classiﬁcation included: adenosis, cylindrical metaplasia, intraepithelial/intraductal/lobular hyperplasia without
atypia, desmoid ﬁbroma.
Figure 2. Fibrous lesions upon histological examination. 59-year-old patient with a history of right breast cancer treated with lumpectomy
and with homolateral nipple retraction that appeared recently. Discovery of a mass on the MRI with irregular shape and contours, located
in the LEQ of the right breast in the mid breast region classiﬁed as BIRADS 4 (a, T1 injected with subtraction) corresponding to ﬁbrocystic
dystrophy (b). Another 46-year-old patient with a BRCA1 mutation and a history of right breast cancer, with breast implants, followed-up by
MRI. Discovery of a mass with regular contours and shape located in the UEQ of the right breast in the deep breast region (c, T1 injected with
s
(
ubtraction) classiﬁed as BIRADS 4 due to a type II curve, corresponding
d). to ﬁbrous restructuring with post-radiotherapy nuclear dystrophy
Correlation  between  MRI  and  biopsies  under  second  look  ultrasound  201
gn leFigure 3. Graphic showing the proportion of malignant and beni
on the MRI.breast  regions  (Kappa  =  0.55)  (Fig.  4).  On  the  other  hand,
cranio-caudal  displacement  of  the  targets  between  the
MRI  and  the  ultrasound  was  moderate  with  almost  perfect
agreement  (Kappa  =  0.97)  of  the  topography  of  the  targets
i
m
a
t
Figure 4. Displacement of lesions between the MRI and the ultrasou
microcalciﬁcations in the left LEQ with a classiﬁcation of BIRADS 4 (mac
the microcalciﬁcations. Discovery on the MRI of two masses in the mid b
with irregular contours and shape classiﬁed as BIRADS 4 (a and b, T1 in
sagittal MPR (d) of the injected T1 sequence with subtraction show the
pectoral muscle. In ultrasound, the two masses can be found in the deepsions based on the breast region where the abnormality is locatedn  the  external  and  internal  quadrants.  Moreover  latero-
edian  displacement  was  also  moderate  with  almost  perfect
greement  agreement  (Kappa  =  0.93)  of  the  topography  of
he  targets  in  the  external  and  internal  quadrants.  The
nd. Patient with a history of right breast cancer. Appearance of
robiopsy planned). MRI carried out for the extension evaluation of
reast region of the UIQ of the left breast in the deep breast zone,
jected with subtraction). The volumetric reconstructions (c) and
 position of the lesions compared to the level of the skin and the
 breast region in contact with the pectoral muscle (e and f).
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omparison  of  the  topography  of  the  targets  by  quadrant
etermined  by  the  MRI  then  by  second  look  ultrasound
howed  high  agreement  (Kappa  =  0.66).  The  hour  topo-
raphic  analysis  showed  a  delay  of  the  lesions  of  more  or
ess  2  hours  between  the  MRI  and  the  ultrasound  with  mod-
rate  agreement  between  the  two  methods  (Kappa  =  0.52).
inally,  the  MRI  overestimated  the  distance  between  the
arget  and  the  nipple  compared  to  the  ultrasound  (Student
-test,  P  = 0.04).
ancer rate according to the MRI appearance
f the lesions
he  rate  of  cancer  found  by  second  look  ultrasound  biopsy
as  identical  for  masses  and  non-masses  (19/79  and  7/29,
espectively).
For  masses,  the  best  criteria  for  MRI  in  favour  of  benig-
ity  in  this  study  were  benign  contours  with  a  negative
redictive  value  (NPV)  of  0.86  (regular  versus  spiculated
nd  irregular,  Fisher  test,  P  =  0.0330,  (Fig.  5)  and  benign
nhancement  curves  VPN  =  1  (type  I  versus  type  II  and  III,
isher  test,  P  =  0.0146,  (Figs.  6  and  7).  The  T1  appearance,
he  T2  appearance,  the  shape  and  the  internal  enhancement
ere  not  good  criteria  to  predict  the  type  of  lesions  (Fisher
est,  P  >  0.0719).  Similarly,  the  size  in  MRI  did  not  make
t  possible  to  predict  the  benign  character  of  the  lesions
Student’s  t-test,  P  =  0.8875).
For  non-masses,  the  distribution  or  the  internal  enhance-
ent  did  not  make  it  possible  to  predict  the  malignant
a
o
(
igure 5. Circumscribed contours versus irregular and spiculated con
ight breast cancer for which a mass with irregular shape and circumsc
eft breast was discovered on the MRI (a, T1 injected with subtraction)
ystrophic origin (b). Another 53-year-old patient sent for an MRI for th
reast, for which we discovered a mass of the UEQ of the right breast, lo
nd two spiculae (c, T1 injected with subtraction). It is a ductal hyperplM.  Nouri-Neuville  et  al.
ature  of  the  lesions,  Fisher  test,  P  >  0.5552  (Fig.  8).  The
egative  predictive  values  of  the  BIRADS  benign  criteria
ere  less  than  0.85  for  non-masses.
The  BIRADS  3  classiﬁcation  on  MRI  (masses  and  non-
asses)  had  a  negative  predictive  value  of  94%  while
he  positive  predictive  value  of  the  BIRADS  4  or  5
lassiﬁcation  in  MRI  was  0.27  (Fisher  test,  P  =  0.0677
Fig.  9).
ancer rate according to the ultrasound
ppearance of the lesions
he  best  ultrasound  criteria  in  favour  of  benignity  were
he  benign  shape  NPV  =  0.90  (round  or  oval  versus  irregular,
isher  test,  P  =  0.0252),  benign  contours  NPV  =  0.91  (cir-
umscribed  versus  irregular  or  spiculated,  Fisher  test,
 =  0.0046)  and  benign  orientation  NPV  =  0.87  (horizontal
ersus  vertical,  Fisher  test,  p  =  0.0018,  (Figs.  8  and  10).
he  depth  of  the  lesion,  echogenicity  and  the  appear-
nce  of  the  posterior  ultrasound  beam  were  not  good
iscriminating  criteria  to  predict  the  malignant  or  benign
haracter  of  the  lesion  (Fisher  test,  P  > 0.53).  The  size
n  the  ultrasound  also  did  not  make  it  possible  to  pre-
ict  the  benign  character  of  the  lesions  (Student’s  t-test,
 =  0.6571).
The  BIRADS  3  classiﬁcation  on  the  ultrasound  had  a  neg-
tive  predictive  value  of  95%.  The  positive  predictive  value
f  the  BIRADS  4  or  5  classiﬁcation  on  the  ultrasound  was  0.27
Fisher  test,  P  =  0.0398).
tours on MRI. 46-year-old patient with an extension evaluation of
ribed contours located in the mid breast region of the UEQ of the
. This mass was classiﬁed as BIRADS 4. It is a ﬁbrous movement of
e exploration of an architectural distortion of the UEQ of the left
cated in the anterior breast region, with discreetly irregular shape
asia with atypia (d).
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Figure 6. Interest of the curve in MRI when characterising a mass. 69-year-old patient with a right axillar lymph node metastasis of breast
cancer (a, T1 injected with subtraction) with a normal ﬁrst mammography/ultrasound evaluation, screening for the primary tumour on
MRI. Discovery of a mass with irregular shape and regular contours (b, T1 injected subtraction), the curve of which shows a wash-out (c),
classiﬁed as BIRADS 4. It is a grade SBR III invasive ductal adenocarcinoma with a triple negative immunohistochemical proﬁle (d).
Figure 7. Interest of benign ultrasound contours and the curve in MRI to characterise a mass. 37-year-old patient with a BRCA1 mutation
with a personal history of right breast cancer, followed-up by MRI. Appearance of an oval mass with well-circumscribed contours located
in the mid breast region of the UIQ of the right breast (a, T1 injected with subtraction) with a type I enhancement curve (b), classiﬁed as
BIRADS 3. This mass discovered on the MRI corresponds to a mass on the ultrasound that was hypoechogenic, oval, well-circumscribed, with
a horizontal orientation, without attenuation, in the mid breast region (c), classiﬁed as BIRADS 3. Due to the history of the patient, this
mass was biopsied. It was a ﬁbrocystic dystrophy (d).
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Figure 8. Nonspeciﬁc appearance of non-masslike enhancement on MRI. 47-year-old patient with onset of right nipple retraction with
mammography and ultrasound without masses or visible calciﬁcations. Discovery on the MRI of enhancement without a segmentary-type
homogeneous mass in the JEQ of the right breast classiﬁed as BIRADS 4 (a, T2 fat sat, and b, T1 injected with subtraction). On the ultrasound,
in the JEQ of the right breast, we found a hypoechogenic mass with irregular contours and shape classiﬁed as BIRADS 4 (c). It is a benign
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sclerosing lesion with adenosis containing microcalciﬁcations (d).
ifference in the appearance of the lesions
inally,  the  MRI  overestimated  the  size  of  the  targets  com-
ared  to  ultrasound  (Student  t-test,  P  =  0.0001)  (Fig.  11).
or  masses,  the  study  showed  that  the  agreement  in  inter-
retation  of  the  benign  versus  suspicious  morphological
riteria  between  the  MRI  and  the  ultrasound  was  very  weak
or  the  shape  (Kappa  =  0.09)  and  weak  for  the  contours
Kappa  =  0.23)  (Fig.  12).  The  BIRADS  3  classiﬁcation  versus
 or  5  was  also  often  different  between  the  ultrasound  and
he  MRI  (Kappa  =  0.11).  The  ﬁve  lesions  classiﬁed  as  BIRADS
 on  the  MRI  and  ultrasound  were  all  benign.
iscussion
his  study  compared  the  clinical,  MRI  and  second  look
ltrasound  data  to  the  results  obtained  after  biopsy.  It
howed  that  the  risk  factors  were  not  reliable  criteria  for
stablishing  an  indication  for  second  look  ultrasound.  The
esions  found  and  biopsied  on  a  second  look  basis  were
ot  more  often  malignant  in  the  population  at  risk  than
n  the  population  without  any  particular  risk  factors.  This
tudy  also  showed  that  circumscribed  contours  and  a  pro-
ressive  enhancement  curve  (type  I)  for  masses  on  MRI
ad  the  strongest  negative  predictive  value  of  greater  than
.85.  For  non-masses,  the  morphological  criteria  were  not
iscriminating.  In  ultrasound,  the  round  or  oval  shape,  cir-
umscribed  contours  and  the  parallel  orientation  to  the  skin
avoured  benignity  with  a  NPV  of  greater  than  0.85.
i
t
b
iThe  correlation  between  abnormalities  detected  on  MRI
nd  those  found  in  second  look  ultrasound  or  mammogra-
hy  is  sometimes  delicate  [3]. The  positioning  of  the  breast
s  different  depending  on  the  imaging  method.  In  MRI,  the
istance  between  the  chest  wall  and  the  glandular  tissue
s  increased  by  the  compression  and  the  procubitus  posi-
ion.  The  position  without  compression  in  decubitus  used  in
ltrasound  reduces  this  distance.  In  the  same  way,  a  slight
ateral  decubitus  is  generally  used  in  ultrasound  in  order  to
etter  spread  out  the  breast.  Carbonaro  et  al.  thus  mea-
ured  by  MRI  the  displacement  of  lesions  between  MRI  and
ltrasound.  The  switch  from  procubitus  to  decubitus  could
isplace  the  tumour  by  30  to  60  mm  in  the  three  direc-
ions  of  space.  The  maximal  displacement  took  place  in  the
ntero-posterior  direction  with  displacement  of  the  tumour
ompared  to  the  level  of  the  sternum  of  60  mm  and  30  mm
ompared  to  the  level  of  the  pectoral  muscle.  On  the  other
and,  according  to  these  authors,  the  displacement  of  the
esion  compared  to  the  skin  or  to  the  nipple  was  less  than
0  mm  [4].  The  ‘‘hour’’  position  of  the  lesion  in  ultrasound
an  also  vary  by  one  or  two  hours  compared  to  the  MRI.  Our
esults  were  in  complete  agreement  with  these  data.  It  is
herefore  essential  that  second  look  ultrasounds  and  mam-
ograms  be  carried  out  after  analysis  of  MRI  images  with
he  help  of  3D  reconstructions  in  order  to  locate  the  lesion
ased  on  relatively  ‘‘ﬁxed’’  markers,  such  as  the  nipple,  the
kin  and  unambiguous  neighbouring  structures  (cysts,  scars,
mplant,  clips).  Our  study  showed  that  the  interpretation  of
he  shape  and  the  contours  of  the  lesion  varied  signiﬁcantly
etween  the  MRI  and  the  ultrasound.  These  results  are  also
n  agreement  with  those  in  the  literature.  The  shape,  size
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Figure 9. Weak positive predictive value of the BIRADS 4 or 5 in MRI. 60-year-old patient with appearance of left nipple retraction with
normal initial mammography and ultrasound. Discovery on the MRI of a mass in the LEQ of the left breast with an irregular shape and
spiculated contours in the deep breast region in contact with the pectoral muscle, classiﬁed as BIRADS 5 (a) corresponding on the ultrasound
to a mass with an irregular shape and spiculated contours also classiﬁed as BIRADS 5 (b). It is a benign lesion: a desmoid ﬁbroma (c). Another
57-year-old patient with a personal history of breast cancer with the appearance of a left axillar adenopathy. Discovery of a mass in the
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estimated  to  be  5%  of  cases  in  which  a  cancer  could  be  found
in  two  of  three  cases  [7].
Table  1  Success  rate  of  second  look  depending  on  the
type  of  discovered  MRI  abnormality  (mass  versus  non-
mass)  and  its  size  [7].
Size  (mm)  Mass  (%)  Non-mass  (%)
<  5  50  —JUQ of the left breast with irregular contours and shape located in
ultrasound to a mass with the same characteristics also classiﬁed a
and  contours  can  be  useful  in  ﬁnding  a  lesion  discovered  by
MRI  on  second  look  ultrasound,  but  perfect  agreement  must
not  necessarily  be  expected  [5].
Despite  these  difﬁculties  related  to  the  switch  from  MRI
to  ultrasound,  several  studies  show  that  it  is  most  often
possible  to  ﬁnd  and  biopsy  lesions  with  ultrasound  and  mam-
mography  that  were  not  found  using  these  methods  before
MRI  [5].  The  success  rate  increases  for  masses  (25  to  62%)  and
decreases  for  non-masses  (11  to  42%)  (Fig.  13)  [5—7]. The
success  rate  for  second  look  mammographies  for  non-masses
appears  to  be  19%  [2].  Foci  with  a  suspicious  character  (type
III  curve)  or  that  are  discovered  during  the  local  extent  eval-
uation  of  breast  cancer  must  be  looked  for  in  second  look
ultrasound.  These  foci  are  found  on  second  look  ultrasound
in  46%  of  cases  [8].  Lesions  with  a  highly  suspicious  appear-
ance  on  MRI  (BIRADS  5)  may  also  be  found  more  often  on  a
second  look  basis  (83%)  than  classiﬁed  lesions  (BIRADS  4),
particularly  masses  with  annular  enhancement  (75%)  and
clumped  non-masslike  enhancement  [6,7].  For  Meissnitzer
[7]  and  Berg  [9],  the  performance  of  second  look  ultrasound
could  depend  on  the  size  of  the  lesions  on  the  MRI.  Ultra-
sound  could  thus  ﬁnd  50%  of  masses  measuring  less  than
5  mm,  56%  of  masses  measuring  6  to  10  mm,  72.5%  of  masses
measuring  10  to  15  mm  and  86%  of  masses  measuring  more
than  15  mm.  For  non-masses,  the  performance  appears  to  be
13%  for  lesions  measuring  6  to  10  mm,  25%  for  those  mea-
suring  10  to  15  mm  and  42%  for  those  greater  than  15  mm
(Table  1)  [7].  The  authors  also  show  that  the  lesions  foundid breast region (d), classiﬁed as BIRADS 4, corresponding on the
DS 4 (e). It is a grade II invasive ductal adenocarcinoma (f).
n  ultrasound  appear  to  be  found  two  or  three  times  more
ften  malignant  compared  to  those  found  on  second  look
ltrasound  and  biopsied  with  a  MRI  check  [7,8]. The  ductal
arcinoma  appear  to  be  found  more  often  on  second  look
ltrasound  than  in  situ  ductal  carcinoma  cases  or  than  inva-
ive  lobular  carcinoma  cases  [5,7]. Age,  the  indication  of
he  MRI  or  the  breast  density  on  MRI,  does  not  appear  to  be
riteria  that  inﬂuence  the  performance  of  second  look  ultra-
ound  [8].  These  results  are  in  agreement  with  this  study,  in
hich  we  did  not  ﬁnd  any  link  between  risk  factors  for  breast
ancer  and  the  probability  of  ﬁnding  cancer  on  a  second  look
asis.  However,  the  MRI  —  ultrasound  correlation  is  not  infal-
ible  when  based  only  on  morphological  criteria  with  an  error
ate  (ultrasound  lesions  that  did  not  correspond  to  the  MRI)5—10  56  13
10—15  72  25
>  15  86  42
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Figure 10. Interest of the orientation of the mass in ultrasound. 44-year-old patient with a luminal invasive ductal carcinoma of the UEQ
of the right breast (a) with right axillar adenopathy (b), the biopsy of which indicated a metastasis of a triple negative invasive ductal
carcinoma. A breast MRI was thus carried out to screen for a second cancer that went unnoticed. On the MRI, there was an oval mass
with regular contours with a type II curve in the JIQ of the right breast located in the deep breast region, classiﬁed as BIRADS 4 (c). This
abnormality corresponded on the ultrasound to a pre-pectoral, attenuating, oval mass with irregular contours and a non-parallel orientation,
classiﬁed as BIRADS 4 (d). It was ductal carcinoma with a triple negative invasive immunohistochemical proﬁle (e).
Figure 11. Overestimation of the size of masses by MRI compared to the ultrasound.
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Figure 12. Disagreement concerning morphological criteria between the MRI and the ultrasound. 46-year-old patient with a history of
right breast cancer. Discovery on the MRI of a mass in the JLQ of the left breast in the deep breast region with an oval shape and regular
contours (a, T1 injected with subtraction) corresponding on the ultrasound to a mass with a vertical orientation and irregular contours and
carc
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3shape classiﬁed as BIRADS 4 (b). It is a grade I invasive ductal adeno
Cases  of  cancer  discovered  in  second  look  ultrasound
often  have  a  nonspeciﬁc  or  subtle  appearance.  According
to  Abe  et  al.,  the  lesions  could  often  appear  to  be  benign,
round  or  oval  in  60%  of  cases  and  isoechogenic  in  30%  of
cases,  without  a  shadow  cone  in  79%  of  cases  and  with  a
parallel  orientation  in  60%  of  cases.  According  to  these  same
authors,  with  regard  to  benign  lesions,  second  look  ultra-
sound  may  still  be  capable  of  distinguishing  63%  of  them,
with  the  remaining  37%  being  considered  suspicious  and  a
biopsy  recommended  [8].  On  the  other  hand,  for  Fiaschetti
a
t
t
i
Figure 13. Mass versus non-mass success rate of the second look. 60
lobular carcinoma in the deep breast region of the right breast. Discove
located at the JUQ in the mid breast region of the right breast (a, sagi
subtraction). The mass of the JUQ corresponds on the ultrasound to an ov
breast region (b). It is a ﬁbrocystic dystrophy (c). 60-year-old patient w
a focal area type enhancement without a mass located in the JEQ of th
MRI (d, T1 injected with subtraction). On the ultrasound, this MRI abnorm
mass with irregular contours and slightly attenuating, classiﬁed as BIRADinoma (c).
t  al.,  the  negative  predictive  value  of  the  second  look  ultra-
ound  in  the  screening  for  lesions  classiﬁed  as  BIRADS  3  on
RI  appears  to  be  97%  [10]. These  latest  data  are  in  agree-
ent  with  the  results  of  our  study,  in  which  we  found  a  NPV
or  the  ultrasound  of  85%  for  MRI  lesions  classiﬁed  as  BIRADS
,  4  and  5.  All  of  the  lesions  classiﬁed  as  BIRADS  3  on  the  MRI
nd  ultrasound  were  benign  (n  = 5).  Our  study  also  showed
he  absence  of  agreement  between  the  BIRADS  classiﬁca-
ions  obtained  by  MRI  and  by  ultrasound.  This  shows  that  it
s  absolutely  necessary  to  carry  out  second  look  ultrasound
-year-old patient sent for an extension evaluation of an invasive
ry of a 5 mm mass with an oval shape and circumscribed contours
ttal cut of an MPR reconstruction of a T1 injected sequence with
al hypoechogenic mass with bi-lobular contours located in the deep
ith a family and personal history of right breast cancer, for which
e right breast in the mid breast region appeared on the follow-up
ality classiﬁed as BIRADS 4 corresponded to a hypoechogenic, oval
S 4 (e). It is a scar sclerosis (f).
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r  mammography  for  abnormalities  classiﬁed  as  BIRADS  3,  4
r  5  on  MRI  and  whose  presence  changes  the  treatment  of
he  patient.  Indeed,  the  satellite  lesions  located  near  a  con-
rmed  tumour  do  not  require  any  additional  investigations
s  long  as  the  total  tumour  volume  does  not  exceed  3  cm
nd/or  it  does  not  change  the  planned  surgery.  On  the  other
and,  if  a  lesion  is  discovered  on  MRI  and  it  could  modify
he  treatment,  this  lesion  must  ﬁrst  be  conﬁrmed  by  a  his-
ological  control  before  any  decision  concerning  treatment
s  made.
In  order  to  improve  practices,  it  is  recommended  that  the
orrespondence  between  the  lesions  biopsied  by  ultrasound
r  second  look  directed  stereotaxis  after  breast  MRI  be  con-
rmed.  For  this,  it  is  possible  to  insert  a  clip  in  the  biopsy  site
nd  to  compare  its  position  compared  to  the  target  lesion
n  the  MRI  using  a  T1  weighted  gradient  echo  sequence,
ithout  fat  saturation,  that  is  sensitive  to  artefacts  with
agnetic  susceptibility  (3D  rapid  EG,  TR/TE,  8/4.6;  matrix,
76  ×  464;  ﬂip  angle  16◦;  voxel  size,  0.8  ×  0.8  ×  0.8  mm)
11].  The  echo  time  can  be  reduced  if  the  clip  to  be
ound  is  small  in  order  to  increase  magnetically  susceptible
a
i
igure 14. Clip. Extension evaluation of an CLI of the UEQ of the right
 patient with a BRCA 1 mutation with a history of triple negative CCI of t
ass in the deep breast region of the left breast, with irregular contour
his mass, which is classiﬁed as BIRADS 4, corresponds on the ultrasou
ontours, located in the mid breast region, classiﬁed as BIRADS 5 (e). A b
he procedure. The position of the clip was then controlled by MRI. The v
n the MRI (f). A new biopsy was thus carried out under MRI (g and h). It
arcinoma.M.  Nouri-Neuville  et  al.
rtefacts  that  make  it  possible  to  detect  the  clip.  Fat  satu-
ation  must  be  avoided,  which  masks  the  drop  in  the  signal
elated  to  the  presence  of  the  clip.  The  detection  of  the  clip
an  be  disturbed  in  patients  with  abundant  glandular  tissue.
f  there  is  disagreement  between  the  biopsy  carried  out  via
ltrasound  and  the  MRI  lesion,  a  biopsy  under  MRI  should  be
ecommended  (Fig.  14).
The  limits  of  this  study  include  the  absence  of  follow-
p  of  non-biopsied  patients.  This  exclusion  criteria  does
ot  allow  us  to  precisely  evaluate  the  negative  predictive
alues  of  the  morphological  criteria  in  MRI  and  in  ultra-
ound.  A  clip  was  not  always  inserted  during  the  second
ook  biopsies.  However,  follow-up  for  at  least  two  years  of
atients  did  not  show  any  targeting  errors  in  the  biopsied
atients.
There  is  no  consensus  concerning  the  measures  to  be
aken  after  discovering  the  MRI  lesion  via  second  look  ultra-
ound  or  mammography.  Certain  teams  suggest  the  following
lgorithms  [2,8]  (Figs.  15  and  16).
If  conﬁrmation  by  control  MRI  of  the  position  of  the  clip
mplanted  during  the  biopsy  is  obtained,  in  case  of  a  benign
 breast (a, injected T1 with subtraction, and b, T1 non-injected) in
he left breast. The MRI makes it possible to discover a retro-areolar
s and shape (c, T1 injected with subtraction, c, T1 non-injected).
nd to a hypoechogenic mass with irregular shape and spiculated
iopsy was carried out with the implantation of a clip at the end of
isualized clip is much more anterior than the suspicious lesion was
 is an invasive lobular carcinoma associated with an in situ lobular
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Figures 15 and 16. Algorithms concerning the measures to be taken after discovery on second look mammography or ultrasound of an MRI lesion.
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istological  result,  MRI  follow-up  is  not  absolutely  neces-
ary.  If  the  biopsy  is  carried  out  outside  the  MRI  target,  a
iopsy  under  MRI  is  then  recommended.  If  the  conﬁrma-
ion  by  control  MRI  of  the  clip  is  not  possible,  in  case  of
 benign  second  look  ultrasound  histological  result,  follow-
p  must  be  carried  out  six  months  after  the  biopsy  in  MRI
2].
In  case  of  a  lesion  with  a  typically  benign  appearance  on
econd  look  ultrasound  or  mammography  (lymph  node  with
 fatty  hilum,  cytosteatonecrosis),  if  no  sample  is  taken,  the
esion  must  be  classiﬁed  as  BIRADS  3  and  controlled  6  months
ater.  Indeed,  the  risk  of  cancer  appears  to  be  reduced  in  this
ituation  (less  than  1%).  The  choice  of  the  follow-up  method
emains  debatable.  The  conferences  of  current  consensus
o  not  recommend  MRI  in  this  indication  and  ‘‘standard’’
ollow-up  by  mammography  with  or  without  ultrasound  is
ustiﬁed  [12—14].
If the  lesion  is  not  found  on  ultrasound  or  mam-
ography  and  if  it  has  a  benign  appearance  on  MRI,
t  can  be  classiﬁed  BIRADS  3  and  monitored  by  MRI.  In
he  absence  of  a  suspicious  MRI  lesion  on  the  second
ook  ultrasound,  in  particular  in  a  patient  at  high  risk,
he  performance  of  an  MR-guided  biopsy  is  recommended
5,6,15].
C
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igure 17. 45-year-old patient sent for an MRI for a local extent eval
nd T1 isosignal. It is located at the UEQ of the left breast in the mid 
aturation (b), T1 without injection (c) and T1 with injection (d). Based o
IRADS 3, but the enhancement curve is a type III (e), so the mass is clas
rregular contours and shape, without posterior attenuation (f). The ma
ancer of the grade II invasive ductal carcinoma type (g).M.  Nouri-Neuville  et  al.
TAKE-HOME  MESSAGES
• Good  MRI  —  ultrasound  agreement  in  terms  of
localisation.
• Masses  found  better  than  non-masses.
• BIRADS  5  found  better  than  BIRADS  4.
• The  biopsy  indications  must  be  wide  with  insertion
of  a  clip  and  a  control  MRI.
• Risk  factors  are  not  reliable  criteria  for  the  indication
of  second  look  ultrasound.
• For  masses  in  MRI,  circumscribed  contours  and
progressive  type  I  enhancement  have  the  strongest
negative  predictive  value  (greater  than  85%).
• For  masses  in  ultrasound,  a  round  or  oval  form,
circumscribed  contours  and  an  orientation  parallel
to  the  skin  have  the  strongest  negative  predictive
value.linical case
 45-year-old  patient  is  sent  for  an  MRI  for  a local  extent
valuation  of  left  breast  cancer.  Fig.  17a  shows  the  injected
uation of left breast cancer. There’s a mass with a T2 hypersignal
breast region. Injected T1 with subtraction (a), T2 with fat signal
n the morphological criteria alone, the mass should be classiﬁed as
siﬁed as BIRADS 4. On the ultrasound it corresponds to a mass with
ss was biopsied and turned out to be a synchronous contralateral
rasou
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[Correlation  between  MRI  and  biopsies  under  second  look  ult
T1  with  subtraction,  Fig.  17b  shows  the  T2  with  fat  signal  sat-
uration,  Fig.  17c  shows  the  T1  without  injection  and  Fig.  17d
shows  the  T1  with  injection.
Questions
1.  Based  on  the  provided  images,  what  abnormality  should
be  described?  What  is  its  BIRADS  classiﬁcation  based  on
these  morphological  criteria?
2.  Fig.  17e  is  an  additional  aspect  of  the  MRI.  What  is  it?
What  does  it  mean?
3.  Fig.  17f  shows  the  ultrasound  image  of  the  abnormality
discovered  on  the  MRI.  The  abnormality  discovered  on
the  MRI  corresponds  on  the  ultrasound  to  a  mass  with
irregular  contours  and  shape,  without  posterior  attenua-
tion,  located  in  the  deep  breast  region.  What  is  its  BIRADS
in  ultrasound?
Answers
1.  Response:  it  is  a  mass  with  a  T2  hypersignal  and  T1  isosig-
nal.  It  is  located  at  the  UEQ  of  the  left  breast  in  the
mid  breast  region.  It  has  a  round  shape  with  circum-
scribed  contours.  It  is  classiﬁed  as  BIRADS  3  based  on
the  morphological  criteria  alone.
2.  Response:  it  is  the  enhancement  curve  of  the  mass.  It
has  a  wash-in  and  a  wash-out.  It  is  a  type  III  curve.
This  negative  functional  criteria  is  added  to  the  previ-
ously  mentioned  benign  morphological  criteria.  The  mass
therefore  becomes  suspicious  and  is  thus  classiﬁed  as
BIRADS  4.
3.  Response:  the  mass  is  classiﬁed  as  BIRADS  4.
The  mass  was  biopsied  and  turned  out  to  be  a  synchronous
contralateral  cancer  of  the  grade  II  invasive  ductal  carci-
noma  type  (Fig.  17g).  The  treatment  of  the  patient  will
therefore  be  modiﬁed.
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